DHX33 expression is increased in hepatocellular carcinoma and indicates poor prognosis

Qiu-Hong Tian; Mei-Fang Zhang; Rong-Guang Luo; Jia Fu; Cong He; Gang Hu; Jing-Sheng Zeng

doi:10.1016/j.bbrc.2016.04.033

DHX33 expression is increased in hepatocellular carcinoma and indicates poor prognosis

Biochem Biophys Res Commun. 2016 May 13;473(4):1163-1169. doi: 10.1016/j.bbrc.2016.04.033. Epub 2016 Apr 9.

Authors

Qiu-Hong Tian¹, Mei-Fang Zhang², Rong-Guang Luo³, Jia Fu², Cong He⁴, Gang Hu⁴, Jing-Sheng Zeng⁵

Affiliations

¹ Department of Oncology, First Affiliated Hospital of NanChang University, NanChang, Jiangxi 330006, China.
² Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China; Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
³ Department of Imaging and Interventional Radiology, First Affiliated Hospital of NanChang University, NanChang, Jiangxi 330006, China.
⁴ Department of General Surgery, First Affiliated Hospital of NanChang University, NanChang, Jiangxi 330006, China.
⁵ Department of General Surgery, First Affiliated Hospital of NanChang University, NanChang, Jiangxi 330006, China. Electronic address: eganzhou@163.com.

PMID: 27073163
DOI: 10.1016/j.bbrc.2016.04.033

Abstract

DEAH-box helicase 33 (DHX33) has been implicated in ribosome biogenesis, mRNA translation and inflammation. However, the role of DHX33 in human cancer is rarely studied. Here, we showed that DHX33 expression was significantly increased in hepatocellular carcinoma (HCC), compared with the adjacent nontumorous tissues. In a cohort of 520 patients, DHX33 expression in HCC was closely associated with tumor size (P = 0.007), serum AFP level (P = 0.011), and tumor capsule (P = 0.030). Kaplan-Meier analysis indicated high DHX33 expression was correlated with worse overall and disease-free survival, and higher recurrence rate. The prognostic value of DHX33 was further confirmed by stratified survival analysis. Multivariate analysis revealed DHX33 as an independent prognostic factor for poor overall survival (Hazard Ratio = 1.772, 95% confident interval: 1.451-2.165, P < 0.0001). Our data therefore suggest DHX33 is overexpressed in HCC and serves as a promising prognostic biomarker for this deadly disease.

Keywords: DHX33; Hepatocellular carcinoma; Immunohistochemistry; Prognosis.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Aged
Aged, 80 and over
Biomarkers, Tumor / metabolism*
Carcinoma, Hepatocellular / diagnosis*
Carcinoma, Hepatocellular / metabolism
Carcinoma, Hepatocellular / mortality*
Carcinoma, Hepatocellular / pathology
China / epidemiology
DEAD-box RNA Helicases / genetics*
DEAD-box RNA Helicases / metabolism
Disease-Free Survival
Female
Gene Expression Regulation, Neoplastic
Humans
Liver Neoplasms / diagnosis*
Liver Neoplasms / metabolism*
Liver Neoplasms / mortality*
Liver Neoplasms / pathology
Male
Middle Aged
Neoplasm Recurrence, Local / diagnosis
Neoplasm Recurrence, Local / metabolism
Neoplasm Recurrence, Local / mortality
Neoplasm Recurrence, Local / pathology
Prevalence
Reproducibility of Results
Risk Factors
Sensitivity and Specificity
Survival Rate
Up-Regulation

Substances

Biomarkers, Tumor
DHX33 protein, human
DEAD-box RNA Helicases